News | May 14, 2025
GlaxoSmithKline Pharmaceuticals posts FY25 PAT at Rs. 915 Cr
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
This marks yet another milestone in our series of successful audits over the past year
The company has posted net profit of Rs. 55.36 crores for the Financial Year ended March 31, 2025
The change of name has been carried on pursuant to the Scheme of Amalgamation
he inspection covering the sterile drug product filling and packaging line, quality systems and quality control laboratories concluded compliance with the principles and guidelines of Good Manufacturing Practice
Topiramate is indicated as a treatment of epilepsy and migraine
The company has posted net profit of Rs. 582.01 crores for the Financial Year ended March 31, 2025
This significant milestone enhances our global regulatory standing
The FDA issued Form 483 with one observation related to building and facility management
Alembic Pharmaceuticals commissions new facility at Pithampur
Subscribe To Our Newsletter & Stay Updated
